Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peritoneal mesothelioma.

R N Taub1, M L Keohan, J C Chabot

  • 1Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, 161 Fort Washington Avenue, New York, NY 10032, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma.

ESMO open·2026
Same author

A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma.

ESMO open·2025
Same author

Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma.

Sarcoma·2016
Same author

High-risk features in radiation-associated breast angiosarcomas.

British journal of cancer·2013
Same author

Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Malignant peritoneal mesothelioma is aggressive, but intensive multimodality treatment shows prolonged survival in select patients. Newer agents offer promise for improved outcomes in this challenging cancer.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Medical Oncology

Background:

  • Malignant peritoneal mesothelioma is an aggressive neoplasm with limited treatment options.
  • Rapid intra-abdominal spread necessitates novel therapeutic strategies.

Purpose of the Study:

  • To evaluate an intensive multimodality treatment regimen for malignant peritoneal mesothelioma.
  • To explore palliative systemic chemotherapy options and promising new agents.

Main Methods:

  • Surgical resection (omentectomy, implant removal) with Port-a-Cath placement.
  • Intraperitoneal chemotherapy (doxorubicin, cisplatin, interferon gamma).
  • Second-look laparotomy with intraoperative hyperthermic perfusion (mitomycin, cisplatin) and whole abdominal radiation.

Related Experiment Videos

Main Results:

  • Prolonged survival observed in selected patients undergoing the intensive regimen.
  • Systemic chemotherapy (doxorubicin, mitomycin) offers palliation for non-candidates.
  • Emerging agents like gemcitabine and pemetrexed show potential efficacy.

Conclusions:

  • Intensive multimodality treatment can lead to prolonged survival in select malignant peritoneal mesothelioma patients.
  • Palliative systemic chemotherapy and novel agents represent important therapeutic avenues.